Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 445 to 455 of 455 entries
Sorted by: Best Match Show Resources per page
Epistemic practices in Bio Art.

AI & society

Anker S.
PMID: 33584019
AI Soc. 2021 Feb 08;1-6. doi: 10.1007/s00146-021-01152-w. Epub 2021 Feb 08.

This paper addresses three aspects of Bio Art: iconography, artificial life, and wetware. The development of models for innovation require hybrid practices which generate knowledge through epistemic experimental practices. The intersection of art and the biological sciences contain both...

Cite
Anker S. Epistemic practices in Bio Art. AI Soc. 2021;1-6doi: 10.1007/s00146-021-01152-w.
Anker, S. (2021). Epistemic practices in Bio Art. AI & society, 1-6. https://doi.org/10.1007/s00146-021-01152-w
Anker, Suzanne. "Epistemic practices in Bio Art." AI & society vol. (2021): 1-6. doi: https://doi.org/10.1007/s00146-021-01152-w
Anker S. Epistemic practices in Bio Art. AI Soc. 2021 Feb 08;1-6. doi: 10.1007/s00146-021-01152-w. Epub 2021 Feb 08. PMID: 33584019; PMCID: PMC7869909.
Copy Download .nbib Format: NLM
In vivo models of cardiac diseases: application to drug development and screening.

Expert opinion on drug discovery

Rokutan H, Anker SD, Springer J.
PMID: 22823972
Expert Opin Drug Discov. 2010 Jan;5(1):65-78. doi: 10.1517/17460440903460299.

Cardiac disease is the top cause of human mortality in the Western world. Current drug therapy for cardiac disease has been established via experimental studies using a variety of in vivo animal models. The purpose of this review is...

Cite
Rokutan H, Anker SD, Springer J. In vivo models of cardiac diseases: application to drug development and screening. Expert Opin Drug Discov. 2010;5(1):65-78doi: 10.1517/17460440903460299.
Rokutan, H., Anker, S. D., & Springer, J. (2010). In vivo models of cardiac diseases: application to drug development and screening. Expert opinion on drug discovery, 5(1), 65-78. https://doi.org/10.1517/17460440903460299
Rokutan, Hirofumi, et al. "In vivo models of cardiac diseases: application to drug development and screening." Expert opinion on drug discovery vol. 5,1 (2010): 65-78. doi: https://doi.org/10.1517/17460440903460299
Rokutan H, Anker SD, Springer J. In vivo models of cardiac diseases: application to drug development and screening. Expert Opin Drug Discov. 2010 Jan;5(1):65-78. doi: 10.1517/17460440903460299. PMID: 22823972.
Copy Download .nbib Format: NLM
Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial.

Journal of the American College of Cardiology

Januzzi JL, Zannad F, Anker SD, Butler J, Filippatos G, Pocock SJ, Ferreira JP, Sattar N, Verma S, Vedin O, Schnee J, Iwata T, Cotton D, Packer M.
PMID: 34556318
J Am Coll Cardiol. 2021 Sep 28;78(13):1321-1332. doi: 10.1016/j.jacc.2021.07.046.

BACKGROUND: The relationship between the benefits of empagliflozin in heart failure with reduced ejection fraction (HFrEF) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) has not been reported.OBJECTIVES: The authors sought to evaluate the relationship between NT-proBNP and empagliflozin effects in...

Cite
Januzzi JL, Zannad F, Anker SD, et al. Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial. J Am Coll Cardiol. 2021;78(13):1321-1332doi: 10.1016/j.jacc.2021.07.046.
Januzzi, J. L., Zannad, F., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Ferreira, J. P., Sattar, N., Verma, S., Vedin, O., Schnee, J., Iwata, T., Cotton, D., Packer, M. (2021). Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial. Journal of the American College of Cardiology, 78(13), 1321-1332. https://doi.org/10.1016/j.jacc.2021.07.046
Januzzi, James L, et al. "Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial." Journal of the American College of Cardiology vol. 78,13 (2021): 1321-1332. doi: https://doi.org/10.1016/j.jacc.2021.07.046
Januzzi JL, Zannad F, Anker SD, Butler J, Filippatos G, Pocock SJ, Ferreira JP, Sattar N, Verma S, Vedin O, Schnee J, Iwata T, Cotton D, Packer M. Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial. J Am Coll Cardiol. 2021 Sep 28;78(13):1321-1332. doi: 10.1016/j.jacc.2021.07.046. PMID: 34556318.
Copy Download .nbib Format: NLM
Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure.

Journal of the American College of Cardiology

Böhm M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, Mahfoud F, Brueckmann M, Jamal W, Ofstad AP, Schüler E, Ponikowski P, Wanner C, Zannad F, Packer M.
PMID: 34556320
J Am Coll Cardiol. 2021 Sep 28;78(13):1337-1348. doi: 10.1016/j.jacc.2021.07.049.

BACKGROUND: Empagliflozin reduces the risk of cardiovascular death or heart failure (HF) hospitalization in patients with reduced ejection fraction. Its interplay with systolic blood pressure (SBP) is not known.OBJECTIVES: The goal of this study was to evaluate the interplay...

Cite
Böhm M, Anker SD, Butler J, et al. Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure. J Am Coll Cardiol. 2021;78(13):1337-1348doi: 10.1016/j.jacc.2021.07.049.
Böhm, M., Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Pocock, S. J., Mahfoud, F., Brueckmann, M., Jamal, W., Ofstad, A. P., Schüler, E., Ponikowski, P., Wanner, C., Zannad, F., Packer, M. (2021). Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure. Journal of the American College of Cardiology, 78(13), 1337-1348. https://doi.org/10.1016/j.jacc.2021.07.049
Böhm, Michael, et al. "Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure." Journal of the American College of Cardiology vol. 78,13 (2021): 1337-1348. doi: https://doi.org/10.1016/j.jacc.2021.07.049
Böhm M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, Mahfoud F, Brueckmann M, Jamal W, Ofstad AP, Schüler E, Ponikowski P, Wanner C, Zannad F, Packer M. Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure. J Am Coll Cardiol. 2021 Sep 28;78(13):1337-1348. doi: 10.1016/j.jacc.2021.07.049. PMID: 34556320.
Copy Download .nbib Format: NLM
Quantifying high flexion postures in occupational childcare as they relate to the potential for increased risk of knee osteoarthritis.

Ergonomics

Laudanski AF, Buchman-Pearle JM, Acker SM.
PMID: 34397308
Ergonomics. 2021 Aug 31;1-12. doi: 10.1080/00140139.2021.1969041. Epub 2021 Aug 31.

High knee flexion postures, despite their association with increased incidences of osteoarthritis, are frequently adopted in occupational childcare. This study sought to define and quantify high flexion postures typically adopted in childcare to evaluate any increased likelihood of knee...

Cite
Laudanski AF, Buchman-Pearle JM, Acker SM. Quantifying high flexion postures in occupational childcare as they relate to the potential for increased risk of knee osteoarthritis. Ergonomics. 2021;1-12doi: 10.1080/00140139.2021.1969041.
Laudanski, A. F., Buchman-Pearle, J. M., & Acker, S. M. (2021). Quantifying high flexion postures in occupational childcare as they relate to the potential for increased risk of knee osteoarthritis. Ergonomics, 1-12. https://doi.org/10.1080/00140139.2021.1969041
Laudanski, Annemarie F, et al. "Quantifying high flexion postures in occupational childcare as they relate to the potential for increased risk of knee osteoarthritis." Ergonomics vol. (2021): 1-12. doi: https://doi.org/10.1080/00140139.2021.1969041
Laudanski AF, Buchman-Pearle JM, Acker SM. Quantifying high flexion postures in occupational childcare as they relate to the potential for increased risk of knee osteoarthritis. Ergonomics. 2021 Aug 31;1-12. doi: 10.1080/00140139.2021.1969041. Epub 2021 Aug 31. PMID: 34397308.
Copy Download .nbib Format: NLM
CARDIOVASCULAR EFFECTS OF NON-INSULIN GLUCOSE-LOWERING AGENTS: A COMPREHENSIVE REVIEW OF TRIAL EVIDENCE AND POTENTIAL CARDIOPROTECTIVE MECHANISMS.

Cardiovascular research

Savarese G, Butler J, Lund LH, Bhatt DL, Anker SD.
PMID: 34390570
Cardiovasc Res. 2021 Aug 13; doi: 10.1093/cvr/cvab271. Epub 2021 Aug 13.

Type 2 diabetes mellitus (T2DM) is highly prevalent and associated with a 2-fold increased mortality, mostly explained by cardiovascular diseases. Trial evidence on older glucose-lowering agents such as metformin and sulfonylureas is limited in terms of cardiovascular efficacy. Since...

Cite
Savarese G, Butler J, Lund LH, et al. CARDIOVASCULAR EFFECTS OF NON-INSULIN GLUCOSE-LOWERING AGENTS: A COMPREHENSIVE REVIEW OF TRIAL EVIDENCE AND POTENTIAL CARDIOPROTECTIVE MECHANISMS. Cardiovasc Res. 2021;doi: 10.1093/cvr/cvab271.
Savarese, G., Butler, J., Lund, L. H., Bhatt, D. L., & Anker, S. D. (2021). CARDIOVASCULAR EFFECTS OF NON-INSULIN GLUCOSE-LOWERING AGENTS: A COMPREHENSIVE REVIEW OF TRIAL EVIDENCE AND POTENTIAL CARDIOPROTECTIVE MECHANISMS. Cardiovascular research, . https://doi.org/10.1093/cvr/cvab271
Savarese, Gianluigi, et al. "CARDIOVASCULAR EFFECTS OF NON-INSULIN GLUCOSE-LOWERING AGENTS: A COMPREHENSIVE REVIEW OF TRIAL EVIDENCE AND POTENTIAL CARDIOPROTECTIVE MECHANISMS." Cardiovascular research vol. (2021). doi: https://doi.org/10.1093/cvr/cvab271
Savarese G, Butler J, Lund LH, Bhatt DL, Anker SD. CARDIOVASCULAR EFFECTS OF NON-INSULIN GLUCOSE-LOWERING AGENTS: A COMPREHENSIVE REVIEW OF TRIAL EVIDENCE AND POTENTIAL CARDIOPROTECTIVE MECHANISMS. Cardiovasc Res. 2021 Aug 13; doi: 10.1093/cvr/cvab271. Epub 2021 Aug 13. PMID: 34390570.
Copy Download .nbib Format: NLM
Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2021.

Journal of cachexia, sarcopenia and muscle

von Haehling S, Coats AJS, Anker SD.
PMID: 34904399
J Cachexia Sarcopenia Muscle. 2021 Dec 13; doi: 10.1002/jcsm.12899. Epub 2021 Dec 13.

The Journal of Cachexia, Sarcopenia and Muscle (JCSM) aims to publish articles with relevance to wasting disorders and illnesses of the muscle in the broadest sense. In order to avoid publication of inappropriate articles and to avoid protracted disputes,...

Cite
von Haehling S, Coats AJS, Anker SD. Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2021. J Cachexia Sarcopenia Muscle. 2021;doi: 10.1002/jcsm.12899.
von Haehling, S., Coats, A. J. S., & Anker, S. D. (2021). Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2021. Journal of cachexia, sarcopenia and muscle, . https://doi.org/10.1002/jcsm.12899
von Haehling, Stephan, et al. "Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2021." Journal of cachexia, sarcopenia and muscle vol. (2021). doi: https://doi.org/10.1002/jcsm.12899
von Haehling S, Coats AJS, Anker SD. Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2021. J Cachexia Sarcopenia Muscle. 2021 Dec 13; doi: 10.1002/jcsm.12899. Epub 2021 Dec 13. PMID: 34904399.
Copy Download .nbib Format: NLM
Kidney Function After Initiation and Discontinuation of Empagliflozin in Patients With Heart Failure With and Without Type 2 Diabetes: Insights From the EMPERIAL Trials.

Circulation

Anker SD, Ponikowski P, Wanner C, Pfarr E, Hauske S, Peil B, Salsali A, Ritter I, Koitka-Weber A, Brueckmann M, Lindenfeld J, Abraham WT.
PMID: 34397263
Circulation. 2021 Oct 12;144(15):1265-1267. doi: 10.1161/CIRCULATIONAHA.121.054669. Epub 2021 Aug 16.

No abstract available.

Cite
Anker SD, Ponikowski P, Wanner C, et al. Kidney Function After Initiation and Discontinuation of Empagliflozin in Patients With Heart Failure With and Without Type 2 Diabetes: Insights From the EMPERIAL Trials. Circulation. 2021;144(15):1265-1267doi: 10.1161/CIRCULATIONAHA.121.054669.
Anker, S. D., Ponikowski, P., Wanner, C., Pfarr, E., Hauske, S., Peil, B., Salsali, A., Ritter, I., Koitka-Weber, A., Brueckmann, M., Lindenfeld, J., Abraham, W. T. (2021). Kidney Function After Initiation and Discontinuation of Empagliflozin in Patients With Heart Failure With and Without Type 2 Diabetes: Insights From the EMPERIAL Trials. Circulation, 144(15), 1265-1267. https://doi.org/10.1161/CIRCULATIONAHA.121.054669
Anker, Stefan D, et al. "Kidney Function After Initiation and Discontinuation of Empagliflozin in Patients With Heart Failure With and Without Type 2 Diabetes: Insights From the EMPERIAL Trials." Circulation vol. 144,15 (2021): 1265-1267. doi: https://doi.org/10.1161/CIRCULATIONAHA.121.054669
Anker SD, Ponikowski P, Wanner C, Pfarr E, Hauske S, Peil B, Salsali A, Ritter I, Koitka-Weber A, Brueckmann M, Lindenfeld J, Abraham WT. Kidney Function After Initiation and Discontinuation of Empagliflozin in Patients With Heart Failure With and Without Type 2 Diabetes: Insights From the EMPERIAL Trials. Circulation. 2021 Oct 12;144(15):1265-1267. doi: 10.1161/CIRCULATIONAHA.121.054669. Epub 2021 Aug 16. PMID: 34397263.
Copy Download .nbib Format: NLM
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.

The New England journal of medicine

Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, Joseph A, Kolkhof P, Nowack C, Schloemer P, Ruilope LM.
PMID: 34449181
N Engl J Med. 2021 Dec 09;385(24):2252-2263. doi: 10.1056/NEJMoa2110956. Epub 2021 Aug 28.

BACKGROUND: Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, has favorable effects on cardiorenal outcomes in patients with predominantly stage 3 or 4 chronic kidney disease (CKD) with severely elevated albuminuria and type 2 diabetes. The use of finerenone in...

Cite
Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med. 2021;385(24):2252-2263doi: 10.1056/NEJMoa2110956.
Pitt, B., Filippatos, G., Agarwal, R., Anker, S. D., Bakris, G. L., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Schloemer, P., Ruilope, L. M. (2021). Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. The New England journal of medicine, 385(24), 2252-2263. https://doi.org/10.1056/NEJMoa2110956
Pitt, Bertram, et al. "Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes." The New England journal of medicine vol. 385,24 (2021): 2252-2263. doi: https://doi.org/10.1056/NEJMoa2110956
Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, Joseph A, Kolkhof P, Nowack C, Schloemer P, Ruilope LM. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med. 2021 Dec 09;385(24):2252-2263. doi: 10.1056/NEJMoa2110956. Epub 2021 Aug 28. PMID: 34449181.
Copy Download .nbib Format: NLM
Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes.

Circulation

Filippatos G, Anker SD, Agarwal R, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Schloemer P, Tornus I, Joseph A, Bakris GL.
PMID: 33198491
Circulation. 2021 Feb 09;143(6):540-552. doi: 10.1161/CIRCULATIONAHA.120.051898. Epub 2020 Nov 16.

BACKGROUND: The FIDELIO-DKD trial (Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease) evaluated the effect of the nonsteroidal, selective mineralocorticoid receptor antagonist finerenone on kidney and cardiovascular outcomes in patients with chronic kidney disease and...

Cite
Filippatos G, Anker SD, Agarwal R, et al. Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes. Circulation. 2020;143(6):540-552doi: 10.1161/CIRCULATIONAHA.120.051898.
Filippatos, G., Anker, S. D., Agarwal, R., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Schloemer, P., Tornus, I., Joseph, A., Bakris, G. L. (2021). Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes. Circulation, 143(6), 540-552. https://doi.org/10.1161/CIRCULATIONAHA.120.051898
Filippatos, Gerasimos, et al. "Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes." Circulation vol. 143,6 (2021): 540-552. doi: https://doi.org/10.1161/CIRCULATIONAHA.120.051898
Filippatos G, Anker SD, Agarwal R, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Schloemer P, Tornus I, Joseph A, Bakris GL. Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes. Circulation. 2021 Feb 09;143(6):540-552. doi: 10.1161/CIRCULATIONAHA.120.051898. Epub 2020 Nov 16. PMID: 33198491; PMCID: PMC7864612.
Copy Download .nbib Format: NLM
Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial.

The lancet. Diabetes & endocrinology

Verma S, Dhingra NK, Butler J, Anker SD, Ferreira JP, Filippatos G, Januzzi JL, Lam CSP, Sattar N, Peil B, Nordaby M, Brueckmann M, Pocock SJ, Zannad F, Packer M.
PMID: 34861154
Lancet Diabetes Endocrinol. 2022 Jan;10(1):35-45. doi: 10.1016/S2213-8587(21)00292-8. Epub 2021 Nov 30.

BACKGROUND: It is important to evaluate whether a new treatment for heart failure with reduced ejection fraction (HFrEF) provides additive benefit to background foundational treatments. As such, we aimed to evaluate the efficacy and safety of empagliflozin in patients...

Cite
Verma S, Dhingra NK, Butler J, et al. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. Lancet Diabetes Endocrinol. 2021;10(1):35-45doi: 10.1016/S2213-8587(21)00292-8.
Verma, S., Dhingra, N. K., Butler, J., Anker, S. D., Ferreira, J. P., Filippatos, G., Januzzi, J. L., Lam, C. S. P., Sattar, N., Peil, B., Nordaby, M., Brueckmann, M., Pocock, S. J., Zannad, F., Packer, M. (2022). Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. The lancet. Diabetes & endocrinology, 10(1), 35-45. https://doi.org/10.1016/S2213-8587(21)00292-8
Verma, Subodh, et al. "Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial." The lancet. Diabetes & endocrinology vol. 10,1 (2022): 35-45. doi: https://doi.org/10.1016/S2213-8587(21)00292-8
Verma S, Dhingra NK, Butler J, Anker SD, Ferreira JP, Filippatos G, Januzzi JL, Lam CSP, Sattar N, Peil B, Nordaby M, Brueckmann M, Pocock SJ, Zannad F, Packer M. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. Lancet Diabetes Endocrinol. 2022 Jan;10(1):35-45. doi: 10.1016/S2213-8587(21)00292-8. Epub 2021 Nov 30. PMID: 34861154.
Copy Download .nbib Format: NLM
Showing 445 to 455 of 455 entries